Update in bridging anticoagulation.

Area of Science:

• Cardiology
• Pharmacology
• Hematology

Background:

• Vitamin K antagonists (e.g., warfarin) require interruption before invasive procedures, posing a thromboembolic risk.
• Heparin bridging therapy, using low-molecular-weight heparin (LMWH) or unfractionated heparin, is a common strategy to mitigate this risk due to its predictable pharmacokinetics.
• Current guidelines address perioperative anticoagulation management despite a lack of definitive randomized controlled trials.

Purpose of the Study:

• To review the clinical challenges and considerations for heparin bridging therapy in patients undergoing invasive procedures.
• To highlight key issues in managing anticoagulation around surgery, including patient selection and optimal heparin dosing.

Main Methods:

• Literature review of existing guidelines and evidence regarding heparin bridging therapy.
• Analysis of the risks and benefits associated with interrupting vitamin K antagonists and initiating heparin.
• Discussion of factors influencing the decision-making process for perioperative anticoagulation.

Main Results:

• Heparin bridging is frequently employed despite limited high-quality evidence from randomized trials.
• Key considerations include identifying suitable candidates for bridging and determining appropriate heparin regimens.
• Optimizing the timing and dosage of parenteral anticoagulants is crucial for patient safety.

Conclusions:

• Heparin bridging therapy is a widely adopted practice for patients on vitamin K antagonists undergoing procedures.
• Careful patient selection and individualized treatment plans are essential for safe and effective perioperative anticoagulation.
• Further research, including randomized trials, is needed to definitively establish the efficacy and optimal use of heparin bridging.